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Re.~utts: Among the 119 women (85% white: mean ego 58.2 ~ 11 5 y), 
48 had a history of CAD or oxtrac~rdlao ntheroscleresia (HX÷), 71 did not 
(HX) ,  At baseline, onty 29% HX+ and 1 ~,  HX o women wore taking LLAs 
By index angiogrephy, 40 (83%) HX. and 42 (5g%) HX . women had CAD 
Among HX women not on LLAs at baseline with newty diagnosed CAD and 
availal0N) LOL data, 96% had LDL levels >100 rag/dr, 63% ~130 mg/dl, and 
25% ~ 1160 mg/dL None we~ takil~l LLAs 6 weoka later, Among HX+ women, 
73% not on LLAs had LOL levels ~, 1go; only 4 were staffed on LLAs~ 
Conctt~on: Infen~ifCal~ of lq~d,toweting therapy was not apparent 6 
w~#ks after a~graphy  in women with r~wly d!agnos~l CAD nor among 
wom~n who had thair diagnosis conlim~d, 
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~ Impalmd Endothe!!al,dependent Vasod!lMIon In 
Vlabl~ ~lschemic Myocardlum Results From 
Reduced Act iv ity of  Nitric Ox ide Synthase 
R.fl Giratdez, B. Sun, J.L. ~er~ L,C. Backer. Johns Hopkm,S Unn~ets~ty 
Schoo~ ot &~ne,  Ba~more. MD~ USA 
Endothelium-~ependent vaso~lation (EDV). med*ated by mf~: oxide from 
mtnC OXtffe sy~thase (NeSt, iS impa:md after myoca~ ischemia.repe~LP 
men. To detern',ue whether abnormal EDV is due to loss of NOS enzyn~ 
Of tO a reduction in NOS activity, o~relative stt~,es were pedormed in dog 
hearts (n = 15) sul:~ected to gO minutes ischemia followed by 3.5 hr reflow. 
M;orovascular EDV was assessed by radmactwe microspberes dunng intra 
coro-,"~ry infusion of 80 #,g/rain acetyfcholme (ACh). NOS acttv~ was mea- 
sured by the ~4C-argmine to t'~C.-cttmline commrs~on assay. Blood flow and 
NOS act~ty were analyzed within infarcted (INF) and norHntarcted (N-INF) 
portions of the risk region, as defined by postmorten TIC staining. Western- 
blots (We) of the endothelial NOS (eNOS) were performed to detect cbe~'~ges 
in the amounts of enzyme presser. Although ACh increased flow by 135"o in 
normal myocardium, there was no significmd increase after ischemia-roper- 
fusion in either INF or N-INF z'~nes NOS actn~y was mit~t reduced cn 
the N-INF zone but a marked 70% decrease was found m the INF zone. 
No C,a ~'-tndel:~ndent activity was evidenced WB showed similar den~ty of 
eNOS bands in control and N-INF areas but a meier decrease was evident m 
INF myocardium. Thus, absent ACh response ~n postischemic myocardium, 
indcatn,,e of impaired EDV, appears to be related to loss of eNOS enzyme m 
infarcted r~ons  and reduced NOS actz~ty w~th n~rmal evels of enzyme m 
viable areas 
Control N-INF INF 
NOS actP.'dy 100 75 (SD 19)" 30 tSD 8)" 
WB ~ensdy 100 100 30 
NOS-% of control: WB-% of ~rontroL *p - 005~ "'p - O0Ot ~'S control 
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[ -~~ Express ion of the Inducible Isoform of Nitric Oxide 
Synthase in Murine Myocard ium Following a 
Myocardial  Infarction 
F. Sam, F.R. Eberli. S. Nosy. DA Siwik. DL.E Chang, C.S. Apstein, 
W.S. ColuccL M)~card~al Biology Unit Boston Un~versi~. MA. USA 
Nitric oxide (NO) exerts pleiotropic effects on the growlh and phenetype of 
cardiac myocytes and fibroblasts ~n vitro. Recently, the inducible isoform of 
NO synthase (NOS2) was detected in myocardium from patients with end- 
stage heart failure. To address the possibility that myocardial NO expression 
modulates cardiac remodeling and fadure; we determir~.ct tim ti,n~ ~.'uurse of 
NOS2 mRNA expression in munne hearts following a myocardial infarction 
(MI). MI was induced in 16 adult CD-1 mice by ligntion of the left coronary 
arte~. Sham-operated mice served as controls (n = 8). At 3, 7, 14 and 28 
days mRNA isolated from the infarct (including the peri-inlarct margin) and 
the remote (i.e., non-infamted portion of the ventricle) was subjected to north- 
em hybridization with cDNAs for NOS2 and atrial natriuretic factor (ANF). MI 
size ranged from 27-60% of ventricle (mean, 43 ~: 3%). tsovolumic pressure 
volume loops demonstrated LV dilation and depressed systolic function at 14 
and 28 days. In the infamted area, NOS2 mRNA was detectable at 3 days, 
peaked at 7 days (approx. 5-told vs. 3 days), and decreased progressively 
at 14 and 28 days. In remote myocardium, NOS2 mRNA was not increased 
at 3 days, but peaked at 7 days, and remained elevated at 14 and 28 days. 
ANF mRNA was increased at all times in both the infarcted and non-infarcted 
areas, Thus, m the mouse heml NOS2 mRNA ts expresse0 m bo[h me m. 
farctod and remote areas of the ventr~le ~ffer a lar~ MI Myocar~a! NO 
production may depress the ftm¢lion Ot pen-infarct myocyles early posl-MI 
~nd moy modulate thc romodeliog o| the remet~ myocar~um late post,MI 
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,-wmpneo/tn m coronary A ~ :  
Ps~oae~ogtnes!s of UnAIbI~ Angina? 
G, L~uT.zo, S,L. Kopecky, JJ, ~ .~,  K: Comwell, A, Mase,, R.~ Frye, 
C.M Weyand Mayo C/m~c Rochef~tac MN and Cathol¢ Un~mffy Rome, 
naly 
BackgK~nd: Recent studms have demonstrated the preserve of activated 
T-tympho(~les in coronary plaques ~nd pe~ra!  t~ Of patients w~h gn. 
stable ang*~ (UA), However, the ~hanlsmS responsible for lymphec~e 
ectwatio~ in UA ate still unknown, The paflem of Cyfoktrm produclKm by 
different subsets Of T . l~es  may ~ov~ mfomlatmn on the nature ot 
the amigemc stlmu!i to wh~h th~ celts have been axe ,  The ~, )fore, we 
assessed the intreceltulsr OJtokine production of CD4* and CD~. T.lympho* 
cytes using three-color flow cylomelry in 15 pls with UA. 1O pts w~lh chronic 
stable angina (SAt. and 10 healthy sueiects (C). 
~ :  After separation by Ficol! gradlsnt penpheral blood mono~u. 
clear ceils were stimulated for 4 houm with phofl:)ol mynetate acetate and 
ionomycm; Brefeldm A was added to inhibit cytokine secretion. Cells were 
stained w~ either an~CD4 FITC/antFCD3 PerCP or antt,CD8 PmCPPam~, 
CD3 FITC and, after membrane pmmea~lizat~n, with PE labeled anltbodtes 
speofic for intedeukm-2 (IL~2), imerferon-}, (IFN-},) and interleukm-4 (IL.4) 
Results: Frequenoes (%) of IL-2, IFN-},, and IL-4 producing cells (mean 
SEt are shown in the fable. 
UA SA C 
CD4* CDa-* CD4-. CDa* CD4* CDa. 
IL-2 15 . -74  42 :1  286± 58  r e2  . -33  15z5  46+.22  
IFN-i- 266 :15"  597 .*7"  15=10 412¢ t16 107 . -6  3~3~3 
IL4  14±09 09~02 25¢t2  r 12~05 ee l02  05z03  
"P - DOt UA~sSAanclC: rp • 001SAvsUAandC 
Conctu..wons Patients wffh UA and SA expressed disease specthc T-cell 
cytokine patterns SA was charactenzed by a high proportion of CD4+ cells 
produong IL-2 and IL-4. UA was assooated wffh a high propomon of CD4+ 
and CD8+ cells produong IFN-~, The high rate of T-cells able to secrete 
IFN-y in UA w,3u~,.1 be consistent with an inteclious pathogenesm 
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[ -~-~ Tissue Factor Antigen and Activity Unstable in 
Coronary Plaques 
PA. Meriini, E. Bramuc~, L Angoli, R. Coppola, R. Anens, P.M. Marmucci. 
Dnnsion of Cardiology, Ospedate Niguarda Mi/an, IRCCS. Po/ctimco S. 
Marteo, Pavra: HeJrmphrlia nd Thremt>osis Center, Milan, Italy 
Rupture or fissunng of a coronary athemsclemtic plaque with subsequent 
thrombosis is consisted the key event in the pathogenesis of ur~lable 
angm~ or ac~ r~,.'o~"~--'~l infarction. Recent sh.,ffies h,~,,o shown that tis- 
sue factor (TF), the primary mitmtor of blood coagulation, is involved in 
platstet deposition and thrombus formation on disrupted human atherescfe- 
relic lesions in tntre, but whether the content of trssue factor is related to the 
clinical expression of coronary syndromes is unknown. The present study 
correlates the dmour~r of tissue factor antigen and a ~  :n human c-u,o- 
nary atbemsclemtic lesion extracted during atheroctomy with the ¢tinicat end 
angiographic presentation of the different coronary syndromes. TF antigen 
was quanUtated through an ELISA (nO/rag plaque weight), and TF ectwity 
was measured, by a novel technique, through a factor Xa generation assay 
(mUlmg plaque weight) in 50 patients (19 stable angina, 24 unstable angina 
and 7 myqcardiat infarotron). In the. whole population there was a close cor- 
relation between the amount of tissue-factor antigen and act~ty (r = 0.87. 
p - 0.0001). T~ssue factor antigen and activity were significantly higher in 
plaques extracted from the 31 patients with unstable angina or myocardial 
infarction (antigen: median 66.1 pg/mg; interquartile range: 43.8..-82.5 pg/mg; 
activity: median 0.22 mU/rng; interquaffile range 0.172-0.41 mU/mg) than 
in 19 patients with stable angina (ant;gen: median 32.4 poJmg, interquartile 
range: 9.8-43.4 pg/mg;p = 0.0001; activity: median 0.131 mU/mg: interquar- 
tile range 0.05-0.164 mU/mg; p = 0.0004). Complex coronary lesions with 
thrombosis at angiography, observed in 23 patients, contained higher levels 
of tissue factor antigen and activity (antigen: median 73.2 pg/mg, i~erquar- 
tile range: 47.5-92.3 pg/mg; activity: median 0.27 mU/mg; interquartile range 
0.159-0.41 mU/mg) than uncomplicated lesions (antigen: median 32.8. in- 
terquartile range: 125-489: p = 0.0001: ectMty: median 0.159 mU/mg: 
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Interquadllo range 0,09-0,21 mU/mg; p = 0,0019), Thus, in plaques ot pa- 
tients with unstable coronnry syndromes, the higher content of tissue factor 
may be related to the thrombotic response to rupture, 
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~ ATP.aenaltlva Potassium Channel Blockers (KA'tp) 
Suppress Monophealc Action Potential Shortening 
and Abolish the 'Second Window of Protection' 
Induced by Is©heroic Preconditioning In Rabbit 
Hearta 
N,L, Bsmardo, M, D'Angoic, A,B, Jan, M,A, Wood, R,C, Kukrsl~, Oiws~on o1 
C~rrllot(~ly, VCU.Modt¢,'# Colle~ of Vtrglnf~, Rlchmen# VA, USA 
D+lckgrouncl; lschemlc pracondlltontng (PC) brings t~botlt a dohtyod phase 
of myocardial protection 24 hours later, We hypothosG~ed lh~t this 'second 
window of protection' (SWOP) Involves the opening ot K^~[, channels, 
Mofhod,~: Seven groups el rabbits wore sttldl~d using the In Wvo model ot 
myocardial Infarction, t, Control, ~., GIIbonclamlde (G) 9,3 mg/kg IP 30 m+n 
before Iseheml~/reparlusicn (I/R), 3, 5.hydroxydea~noato (~IHD) 5 mgtkg IV 
15 rain before I/R 4, Sh~m operated ~4 hrs prior to I/R, 5, PC • preoondltloned 
with four ~-min cerennPf oocltmions, each separated by 10 rain el repeduslen, 
24 hm before l/R, 6, PC + G, 7, PC .  [~HD, All mbblts undc~ent 30 mln ot 
corona,y occlusion followed by 3 hrs of ropaduslon, Risk area was delineated 
by Ev~n's bhrs dye and Inlamt el~o w~s determined by tetmzollum staining, 
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Resettle: A s~gntttcnnt reduction in inforct sl~o was observed in PC which 
was blocked bv G and 5HD These .~po('.iltc K^r[, channel blockom signifi- 
cantly suppressed APD shortening in PC hearts. 
Corclusion: The 'SWOP' afforded by PC is mediated via the opening of 
K~e channels 
Optimizing Heart Failure Therapy: Latest 
Strategies 
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8~' -  1--~ Irbesartan Comb:ned With Conventional Therapy, 
Including Anglotensln Convertln~ Enzyme 
Inhlbltom, In Heart Failure 
M, Tonkon, N. Awes, I, Niazi, P Henley, L. Bamch, C,-$. Lin, D, Costagliola, 
G, Cucinotta, R.A, Wolf, A.J. Block for the Irbesartan Heart Failure Group. 
Anaheim Heart & Research Institute, Anaheim, CA, USA 
Irbesartan (IRBE; BMS/Sanofi) efficacy and tolorability, combined with con- 
ventional therapy including angiotensln converting enzyme inhibitors (ACE-Is), 
was evaluated in a double-blind, placebo-cantrolle ' (PBO), pilot study of pa- 
tients (pts) with mild-to-moderate heart failure (HF; NYHA Class II or III) 
and left ventricular ejection I:action (LVEF) ~40%, on diuretic ('>2 wks) and 
ACE-I (_-6 wks) therapy. Pts with 2 consistent Modified Naughton exemise 
tolerance tests (ETTs) were randomized to IRBE (n = 57) [starting doses: 
12.5 rag, 37.5 mg, or 75 mg; titrated to 150 mg as tolerated] or PBO (n = 52) 
QD. ACE-I therapy continued. Angiotensin II (All) and plasma resin activity 
(PRA) were studied in 20 pts. Pts were mainly NYHA Class II (79%), male 
(76%), white (82%), with ages equally ~ and <65. 
PRA and All increases were consistent with All receptor blockade. IRBE 
was well tolerated: serious adverse events were rare in both groups; no 
deaths occurred. More PBO pts required supplemental diuretics than did 
IRBE pts (21% vs 12%). 
ETT (soc) LVEF (units) All (pg/mL) PRA (nQ~ml.hr) 
median change moon change 
IRBE 63,5, 2t-t0['  52 (32~7,J) pro: 35, post: 6.9 pro: 0:4, post: 2t,3 
Pad 47,0, - 6-131' 24  ( 0.4-5 t' pro: 0.8, pent'. 2,0 pm 79, post 14 1 
'2r, th-75Ih qunntlles; vskloe in 0 represent I)5% confidence limits. 
Conclusion: IRBE, combined with conventional therapy including ACE.I, 
produced favorable trends in ETT and LVEF and was well tolerated in pfs 
with mlld4c.moderofo HF, 
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~ Angloteneln II Receptor Blockade Combined to 
ACE-Inhibition Improves Loft Ventd©ulsr Ollatlon 
and Exomlae Ejection Fraction In Congestive Heart 
Failure 
M Tecehi, S, Rcennio, A+ An=ulni, A, Sposi, 0, MaftictL G.B Grassl 
Hospital, Rome: HS, R, Milan, Italy; U,P,M.B., Galveston, TX, USA 
Angtotnnsin It type t receptor antagonist Iossrtan (LOS) has recently emerged 
as a valgable alternative to ACE.inhibltors (ACEI) in the manegemonl of con. 
gestivs heart latium (CHF)~ Aim el this study was to determine if the assn. 
ciation of LOS; and ACEI in pts wilh CHF may enhance the wel!.mcegeized 
banefl(~tal effects of ACEI atone on left ventflculsr (LV) dimensions and func- 
tion as assessed by 2D echocardiography at rest and dunng submaximal 
stlpine bicycle exercise (SBE), Seventy.throe pts (74% male, age 64 :t 6 ym) 
with Impaired systolio LV function (EF 28 ~ 9%) and stable mild to moder. 
ate CHF (NYHA (:tess 2, t -t 0.4) were mndomltnd in e double blind fashmn 
to recelvo LOS 50 mg/d (n =, 42) or placebo (P, n ~ 31) in addition to ACEI 
(enslapriL mean dose 29 mg/d or ceptopril, mean dose 86 rag/d) for 3 months. 
All pts were on dlgoxln and diuretics. The two groups were comparable in age, 
goader, El:, LV ond.dlastotie (EDVI) and end.systolic (ESVi) volume inde,, at 
rest and daring SBE. After throe months, both groups showed improved EF 
and LV volumes with respect to values at randomization (p .  091). How. 
evor, treatment with LOS rosulted in significantly greater =mprovement ot LV 
dimensions and function with respect to P, as shown in the Table. 
ACEI * LOS ACEI + P 
At 3 months Rest SBE Rest SBE 
EF (%) 31 t 10" 36 t 129 28 t 12 32 t S 
EOVI (mPm ~) 79 t 13" 71 :t 10 t 87 .t 14 7G ¢ 11 
ESVI (mitre ~) 69 t 10" 58 ~ 8 t ;'2 i 10 66 *. 9 
Mean "~ SD, "p • 0.05 vs ACEI + P Rest: tp. OOS vs ACE + P SBE 
In conclusion, those results indicate that LOS combined to ACEI may 
confer incremental functional benefit as compared to ACEI alone in pts with 
CHF 
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~ '~ Clinical Benefits of Long-term Anglotensin II 
Receptor Blockade in Patients With Severe 
Symptoms of Congestive Heart Failure Despite Full 
Anglotensln Converting Enzyme Inhibition 
G, Hammff, I. Blautarb, D. Mancini, S. Katz, R. Bijou. G. Jondoau, 
M,-T, Olivan. S. Thomas, T. LeJemtol. The Atb~,; C,,ra,,.in College or 
Medicine, Bronx, NY, USA 
Attar initial improvement, symptoms tend to recur in patients with congestive 
heart failure (CHF) despite angiotensin converting enzyme (ACE) inhibition 
at maximally recommended o, tolerated dose, digoxin and loop diuretics. 
The present study was undertaken to determine if the addition of All type 
1 (ATt) receptor blockade to full ACE inhibition would improve functional 
class (FC, NYHA) and maximal exercise capacity (peak VO2, mt/kg/min) in 
patients with severe CHF, i.e. peak VO2 < 16 and FC Ill-IV at baseline (BL). 
Thirty-two patients (mean age 61 yrs, ejection fraction 26%) were randomized 
to placebo (P) or Iosartan (L) 50 mg daily. They were evaluated at 3 and 6 
rodS. Results were as follows: 
BL 3 mes 6 mos 
t. F L P L P 
FC 3,2 3,0 2.9 3.0 2,5" 3.0 
Peak VO2 13.1 14.5 14.7 14.7 15.1" 14.2 
• =p- 0.05Lvs P:L(n = 15);P(n = 14) 
L at a daily dose of 50 mg was well tolerated by all patients. Three 
patients were lost to follow up. In conclusion, long-term ATt receptor blockade 
improves symptoms and exercise capacity in patients with CHF who are 
severely symptomatic despite full ACE inhibition, digitalis and diuretics. 
